Kyntra Bio, Inc. · NASDAQ:KYNB
Kyntra Bio — Investor Presentation (September 2026)
33 slides from Kyntra Bio's investor presentation, September 2026
Slide 1: Kyntra Bio Corporate Presentation September 2026
Kyntra Bio Corporate Presentation I September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements regarding Kyntra Bio’s strategy, future plans and prospects, including statements regarding its commercial products and clinical programs and those of its partners Fortis and UCSF. These forward- looking statements incl
Slide 3: Investment Highlights
Investment Highlights Advancing mid- and late-stage assets in prostate cancer and rare disease Balance Sheet Transformation Completed • Completed balance sheet transformation and reduced the maximum aggregate payments under the NQ royalty financing obligation from $125 million to $65 million, a $60
Slide 4: FG-3246 & FG-3180 Program
Kynira BIO FG-3246 & FG-3180 Program
Slide 5: Prostate Cancer Has a High Unmet Need for Treatment Options in Late-Stage Disease
Prostate Cancer Has a High Unmet Need for Treatment Options That Extend Survival in Late-Stage Disease Prostate cancer is the second ~ 65,000 drug treatable mCRPC most common cancer type cases in the U.S. annually of men will be diagnosed with prostate 13% cancer at some point during their lifetime
Slide 6: CD46 as a Novel Tumor Selective Target in mCRPC
CD46 as a Novel Tumor Selective Target in mCRPC CD46 • Multi-functional protein, overexpressed in cancer • Negatively regulates the complement system and helps tumors evade complement-dependent cytotoxicity • Highly expressed in mCRPC and other solid tumors with limited expression in normal tissues
Slide 7: Targeting a Novel Epitope of CD46 Has Therapeutic and Diagnostic Potential
Targeting a Novel Epitope of CD46 Has Therapeutic and Diagnostic Potential FG-3246 FG-3180 PET Therapeutic Imaging Agent Targeting antibody + MMAE payload Targeting antibody + 89Zr tracer YS5 is a fully-human, full length, Demonstrated specific uptake in CD46 YS5 antibody: Offers an androgen recepto
Slide 8: Phase 1 Monotherapy Study of FG-3246 in Patients with mCRPC
Phase 1 Monotherapy Study of FG-3246 in Patients with mCRPC First-in-human, dose-escalation with dose expansion study Dose Escalation (n=33) Dose Expansion (n=23) Main Eligibility Criteria Dose Levels Two Cohorts • Metastatic CRPC by PCWG3 criteria 0.1 mg/kg Same eligibility as dose escalation • Pri
Slide 9: Phase 1 Monotherapy Study of FG-3246: Baseline Characteristics
Phase 1 Monotherapy Study of FG-3246: Baseline Characteristics Adenocarcinoma study cohort (N = 51) Prior Systemic Therapies, n (%) Median age, years (range) 69 (42 – 81) Androgen deprivation Medical 47 (92.2) Race, n White/Black/Asian/Native American 43 / 5 / 2 / 1 Leuprolide 46 (90.2) Other LHRH/G
Slide 10: FG-3246 Demonstrated Meaningful Monotherapy Clinical Activity in 5L+ mCRPC Patients
FG-3246 Demonstrated Meaningful Monotherapy Clinical Activity in 5L+ mCRPC Patients Phase 1 dose escalation and expansion study results in biomarker unselected and heavily pre-treated patient population with median of 5 prior lines of therapy Efficacy analysis included 40 patients from the 8.7 7.5 d
Slide 11: FG-3246 Phase 1 Monotherapy Safety Profile Consistent with Other MMAE-ADCs
FG-3246 Phase 1 Monotherapy Safety Profile Consistent with Other MMAE-ADCs All Grades by Patient (≥ 10%) All Grades N (%) ≥ Grade 3 N (%) All Grades by Patient (≥ 10%) All Grades N (%) ≥ Grade 3 N (%) Fatigue 25 (56.8) 3 (6.8) Blood alkaline phosphatase ↑ 9 (20.5) 1 (2.3) Weight decreased 23 (52.3)
Slide 12: Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in mCRPC
Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in mCRPC Key inclusion criteria Study endpoints • Progressive mCRPC per PCWG3 criteria • Primary Endpoint for Phase 1b: Determine maximally tolerated dose (MTD) • Progressed on at least 1 prior androgen-signaling inhibitor and recommended
Slide 13: Encouraging Anti-Tumor Activity in Phase 1b/2 Study of FG-3246 with Enzalutamide
Encouraging Anti-Tumor Activity Observed in the Phase 1b/2 Investigator-Initiated Study of FG-3246 in Combination with Enzalutamide in mCRPC Phase 1b/2 results in biomarker unselected patients, Phase 1b/2 results in patients who progressed majority of who progressed on ≥2 prior ARPIs on 1 prior ARPI
Slide 14: Higher Tumor Uptake of FG-3180 (PET46) was Associated with PSA50 Response
Higher Tumor Uptake of FG-3180 (PET46) was Associated with PSA50 Response PSA50 Response P-value Yes (n=7) No (n=16) 11.68 9.24 SUVmax-ave [9.91-13.88] [7.98-10.64] 0.109 9.57 7.58 SUVmax-ave/ SUVmean blood pool [9.24-11.93] [6.66-9.80] 0.053 Results show FG-3180’s potential as PET imaging biomarker
Slide 15: FG-3246 + Enzalutamide Combination Safety Profile Consistent with Monotherapy
FG-3246 + Enzalutamide Combination Safety Profile Consistent with FG-3246 Monotherapy TRAEs Summary Evaluable patients (n=41) n (%) Any grade 41 (100) Grade ≥ 3 9 (22.) Serious TRAEs 3 (7.3) Leading to death 0 (0) Leading to FG-3246 15 (36.6) discontinuation • Neutropenia risk was successfully mitig
Slide 16: FG-3246 Shows Potential Competitive Survival Benefit vs 2L Therapies in Late-Stage Trials
FG-3246 5L+ Monotherapy and 2L+ Combination Therapy Show Potential Competitive Survival Benefit in Biomarker Unselected Patient Population vs 2L Therapies in Late-Stage Trials* Patient Therapeutic | rPFS (months) Phase 3 Trial Sponsor Selection Comparator 1 2 3 4 5 6 7 8 9 10 11 12 Rucaparib 11.2 TR
Slide 17: FG-3246 and FG-3180 Phase 2 Monotherapy Trial Initiated
FG-3246 and FG-3180 Phase 2 Monotherapy Trial Initiated Interim results expected in 4Q 2026 Phase 2 - FG-3246 Dose Optimization in Post-ARPI, Pre-Chemo mCRPC, All Comers (US only) Primary Endpoint: Optimal dose for Phase 3 based on efficacy, safety, and PK Expected Secondary Endpoints: rPFS, PSA50,
Slide 18: FG-3246 Phase 2 Monotherapy Trial: Three Main Design Elements
FG-3246 Phase 2 Monotherapy Trial: Three Main Design Elements Driving the Potential for Increasing rPFS versus the Phase 1 Study (8.7 months) Further validated by Phase 1b/2 Combination IST Use of three of the Use of primary Moving upline to patients highest doses (1.8mg/kg; prophylaxis G-CSF to who
Slide 19: Strong Enrollment Momentum and Highly Engaged Sites in the Phase 2 Monotherapy Study
Strong Enrollment Momentum and Highly Engaged Sites in the Phase 2 Monotherapy Study Clinical Sites Currently Activated and in Startup Interim analysis expected in 4Q 2026 Activated 23 In Startup 1 19
Slide 20: FG-3246 and FG-3180 Near-Term Development Highlights
FG-3246 and FG-3180 Near-Term Development Highlights Development strategy provides significant optionality in prostate cancer alone Robust Phase 2 monotherapy trial …unlocks multiple registrational pathways in pre-chemo mCRPC… sequentially or in parallel • Designed to select dose for optimal benefit
Slide 21: FG-3246 Program Recent & Upcoming Catalysts
FG-3246 Program Recent & Upcoming Catalysts 2Q 2025 3Q 2025 1Q 2026 4Q 2026 FG-3180 IND Initiated Phase 2 FG- Topline results from the Interim analysis from Clearance 3246 monotherapy trial, investigator sponsored study Phase 2 FG-3246 of FG-3246 + enzalutamide including FG-3180 monotherapy trial •
Slide 22: FG-3246 and FG-3180 Present Unique Opportunity in mCRPC
FG-3246 and FG-3180 Present Unique Opportunity in mCRPC Compelling Results in Two Phase 1 Studies FG-3246 was clinically active as monotherapy and in combination with enzalutamide Novel Mechanism of Action and Potential Consistent Safety Profile First-in-Class Opportunity Adverse events consistent w
Slide 23: Roxadustat Program
Kynira BIO Roxadustat Program
Slide 24: Roxadustat is a Global First-in-Class, Oral HIF-PH Inhibitor
Roxadustat is a Global First-in-Class, Oral HIF-PH Inhibitor 2019 Nobel Prize In Physiology or Medicine "for their discoveries of how cells sense and adapt to oxygen availability." Awarded jointly to: William G. Kaelin Jr. Harvard University Peter J. Ratcliffe Increases hemoglobin (Hb) by Approved f
Slide 25: Anemia Associated with Lower-Risk MDS Represents a Significant Opportunity
Anemia Associated with Lower-Risk MDS Represents a Significant Opportunity Anemia is the hallmark symptom of MDS that gives rise to significant morbidity ~74K patients live with MDS in the U.S. Prevalence, United ~55K States, 2025 Patients are ~90% suffering from anemia and its ~74K LR-MDS negative
Slide 26: Anemia of LR-MDS: Phase 3 Opportunity Based on MATTERHORN Subgroup Results
Anemia of LR-MDS: Phase 3 Development Opportunity Based on Post Hoc Subgroup Results from MATTERHORN Phase 3 Trial In patients with high transfusion burden1, roxadustat showed promising TI benefits compared to placebo No. of patients with Roxadustat Placebo 8-wk RBC TI 8-wk RBC TI response (% [95% C
Slide 27: Roxadustat May Elevate the Standard of Care in 2L+ LR-MDS-Anemia
Roxadustat May Elevate the Standard of Care in 2L+ LR-MDS-Anemia Target indication: Treatment of anemia in Del(5q) (~10%) RS+ RS- (30-40%) (50-60%) patients with LR-MDS and 1L Lenalidomide Luspatarcept ESA1 HTB who are refractory to, Luspatercept intolerant to, or ineligible for, prior ESA treatment
Slide 28: Potential Pivotal Phase 3 Trial Overview
Potential Pivotal Phase 3 Trial Overview Opportunity to develop internally or with a strategic partner Patient Population Safety • High transfusion burden: Patients requiring ≥ 4 pRBC Management of potential thrombotic risk through: units in two consecutive 8-week periods prior to • Eligibility crit
Slide 29: Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS
Significant Opportunity for Roxadustat in Anemia Associated with LR-MDS • Significant unmet need despite recent approvals Substantial unmet need in • Opportunity for new therapeutic agents that are more effective in RS- patients LR-MDS anemia • No other oral treatments for anemia of LR-MDS commercia
Slide 30: Balance Sheet Transformation
Balance Sheet Transformation
Slide 31: Material Reduction of NQ Royalty Financing Obligation
Material Reduction of NQ Royalty Financing Obligation Addressed Final Remaining Long-Term Liability on Balance Sheet Total financing obligation reduced by $60 million Reduction of the maximum aggregate payments under the agreement from $125 million to $65 million, a $60 million savings Transaction t
Slide 32: KYNB Balance Sheet Transformation Complete Over Two-Year Period
KYNB Balance Sheet Transformation Complete Over Two-Year Period Reduced Total Potential Gross Liabilities by over $350 Million in Exchange for Payments of ~$150 Million $400 SF Lease $368.7M Settlement SF Lease ($12.0) ($12.0) Settlement $350 ($10.5) ($0.5) MSTV Term Loan Interest ($93.2) $300 $137.
Slide 33: Thank You
Thank You For more information contact ir@kyntrabio.com NASDAQ: KYNB